PET Evaluation of Amyloid Clearance Following Anti-Aβ Monoclonal Antibody Therapy: Preliminary Findings in 25 Patients (EANM 2026) - Sep 29, 2026 - Abstract #EP-0684; "Materials and We report real-world longitudinal amyloid PET data from 26 treatment courses (corresponding to 25 patients) receiving lecanemab (n=9) or donanemab (n=17) who completed 6 months of therapy. Anti-amyloid therapy was safely implemented, achieving rapid, yet heterogeneous, amyloid removal after six months."
Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
|
|
A. Samanes Gajate 1; A. Ghirelli 2, 3; G. Pepe 1; A. Panzacchi 1; S. Vadala’ 1, 4; G. Cecchetti 2; E. G. Spinelli 2, 3; G. Rugarli 2, 3; S. Pisano 2; F. Agosta 2, 3; M. Filippi 2, 3; A. Chiti 1, 3
|